MacroGenics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MacroGenics and other ETFs, options, and stocks.

About MGNX

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. 

CEO
Eric Risser
CEOEric Risser
Employees
293
Employees293
Headquarters
Rockville, Maryland
HeadquartersRockville, Maryland
Founded
2000
Founded2000
Employees
293
Employees293

MGNX Key Statistics

Market cap
276.18M
Market cap276.18M
Price-Earnings ratio
-3.91
Price-Earnings ratio-3.91
Dividend yield
Dividend yield
Average volume
2.22M
Average volume2.22M
High today
High today
Low today
Low today
Open price
$4.10
Open price$4.10
Volume
2.61K
Volume2.61K
52 Week high
$4.56
52 Week high$4.56
52 Week low
$1.19
52 Week low$1.19

Stock Snapshot

As of today, MacroGenics(MGNX) shares are valued at $4.28. The company's market cap stands at 276.18M, with a P/E ratio of -3.91.

On 2026-05-19, MacroGenics(MGNX) stock opened at $4.10, reached a high of —, and a low of —.

The MacroGenics(MGNX)'s current trading volume is 2.61K, compared to an average daily volume of 2.22M.

In the last year, MacroGenics(MGNX) shares hit a 52-week high of $4.56 and a 52-week low of $1.19.

In the last year, MacroGenics(MGNX) shares hit a 52-week high of $4.56 and a 52-week low of $1.19.

MGNX News

TipRanks 6d
MacroGenics reports Q1 EPS (58c), consensus (55c)

Reports Q1 revenue $20.78M, consensus $15.24M. “We are very pleased to report a strong start to the year, building on the momentum generated in 2025. These resu...

TipRanks 7d
MacroGenics Sells Maryland Biologics Manufacturing to Bora

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Analyst ratings

57%

of 7 ratings
Buy
42.9%
Hold
57.1%
Sell
0%

People also own

Based on the portfolios of people who own MGNX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.